Paris-based biotechnology company Cellectis (NASDAQ: CLLS) has announced the first patient in the U.S. to receive a dose of its UCART22 allogeneic CAR T-cell therapy product candidate that was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback